Bayer submits Algeta's radium-223 dichloride in US and EU
This article was originally published in Scrip
Bayer HealthCare has submitted a new drug application to the US FDA and a marketing authorization application to the European Medicines Agency for radium-223 dichloride (radium-223) for the treatment of castration-resistant prostate cancer patients with bone metastases.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.